BeOne Medicines Ltd. - Sponsored ADR (ONC) reported $1.5 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 32.8%. EPS of $0.58 for the same period compares to -$1.43 a year ago.
The reported revenue represents a surprise of +3.19% over the Zacks Consensus Estimate of $1.45 billion. With the consensus EPS estimate being $1.60, the EPS surprise was -63.75%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how BeOne Medicines Ltd. - Sponsored ADR performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Net product revenues: $1.48 billion versus $1.45 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +32.1% change.
- Revenues- Product Revenue- TEVIMBRA: $181.99 million versus the two-analyst average estimate of $191.33 million.
- Revenues- Product Revenue- BRUKINSA(Zanubrutinib): $1.15 billion versus the two-analyst average estimate of $1.09 billion.
View all Key Company Metrics for BeOne Medicines Ltd. - Sponsored ADR here>>>
Shares of BeOne Medicines Ltd. - Sponsored ADR have returned +0.6% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BeOne Medicines Ltd. - Sponsored ADR (ONC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
